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The discovery of therapies that modulate Pseudomonas aeruginosa virulence or that can eradicate chronic P. aeruginosa lung
infections associated with cystic fibrosis (CF) will be advanced by an improved understanding of P. aeruginosa behavior in vivo.
We demonstrate the use of multiplexed Nanostring technology to monitor relative abundances of P. aeruginosa transcripts
across clinical isolates, in serial samples, and for the purposes of comparing microbial physiology in vitro and in vivo. The ex-
pression of 75 transcripts encoded by genes implicated in CF lung disease was measured in a variety of P. aeruginosa strains as
well as RNA serial sputum samples from four P. aeruginosa-colonized subjects with CF collected over 6 months. We present data
on reproducibility, the results from different methods of normalization, and demonstrate high concordance between transcript
relative abundance data obtained by Nanostring or transcriptome sequencing (RNA-Seq) analysis. Furthermore, we address con-
siderations regarding sequence variation between strains during probe design. Analysis of P. aeruginosa grown in vitro identi-
fied transcripts that correlated with the different phenotypes commonly observed in CF clinical isolates. P. aeruginosa transcript
profiles in RNA from CF sputum indicated alginate production in vivo, and transcripts involved in quorum-sensing regulation
were less abundant in sputum than strains grown in the laboratory. P. aeruginosa gene expression patterns from sputum clus-
tered closely together relative to patterns for laboratory-grown cultures; in contrast, laboratory-grown P. aeruginosa showed
much greater transcriptional variation with only loose clustering of strains with different phenotypes. The clustering within and
between subjects was surprising in light of differences in inhaled antibiotic and respiratory symptoms, suggesting that the path-
ways represented by these 75 transcripts are stable in chronic CF P. aeruginosa lung infections.
Several factors complicate the comparison of in vitro studies onPseudomonas aeruginosa with infections in the cystic fibrosis
(CF) lung. First, many different P. aeruginosa strains cause CF
lung infections; thus, reliance on commonly used laboratory
strains might limit our understanding of P. aeruginosa in CF (1–
3). Second, laboratory or cell culture studies rarely incorporate
coinfecting species and lack components of the lung environment,
such as immune response factors, that shape P. aeruginosa pheno-
types (4, 5). We know little about how these environmental stim-
uli influence P. aeruginosa (6–8). To complicate matters further, a
single CF sputum sample contains mixtures of P. aeruginosa ge-
notypes and phenotypes. A recent study has suggested that a mix-
ture of strains influenced traits such as drug response in ways that
were difficult to predict from the study of single strains (9). Clin-
ical isolates of P. aeruginosa, even from the same respiratory sam-
ple, can have striking differences in phenotypes, including colony
morphology, quorum-sensing regulation, and motility (9–13),
and recent data highlight that there is gene expression diversity
even among phenotypically similar strains (9). Given the signifi-
cant limitations of the aforementioned laboratory approaches,
novel methods for directly interrogating population-level micro-
bial gene expression in the CF lung are needed to provide accurate
information about the growth and virulence of P. aeruginosa in
the CF airway.
While some of the P. aeruginosa phenotypes that evolve in the
CF lung (6–8) are associated with negative clinical outcomes, it is
not yet known whether variation in the respiratory health of indi-
viduals with CF and chronic P. aeruginosa lung infection is directly
due to changes in pathogen state or the relative ratios of subpopu-
lations with different phenotypes. Several studies have identified
correlations among strain phenotypes in the laboratory to patient
outcomes. In one study in children, certain morphological fea-
tures of P. aeruginosa colonies were more common in cases where
antibiotics failed to eradicate the organism (14). Mayer-Hamblett
et al. (15) found that augmented pyoverdine production and at-
tenuated protease production best distinguished infection stage
(i.e., new-onset, intermittent, or chronic). This group of investi-
gators also reported that mucoidy and reduced twitching motility
were predictors of worse lung disease. Detection of either P.
aeruginosa mucoid colony phenotype or LasR loss-of-function
phenotype is associated with poor prognosis (8, 16–18). Thus, one
explanation for varied patient health is changes in the dominant
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populations within the lung. Alternatively, other factors in the
lung, such as changes in coinfecting bacteria, fungi, or viruses, or
other changes in host status may influence host phenotype. Inves-
tigations of P. aeruginosa transcripts from clinical samples re-
vealed that the expression of genes related to iron homeostasis
(19), virulence (20, 21), and hypermutability (22) vary consider-
ably among subjects, but the causes or consequences of these
changes are not yet known. These questions represent a signifi-
cant community-wide challenge.
Here, we report our novel application of Nanostring digital
multiplexed gene expression technology (23) to serially quantify
the expression levels of 75 P. aeruginosa mRNA transcripts asso-
ciated with the activity of specific physiological pathways (i.e.,
biofilm production, quorum sensing, virulence, iron metabolism,
and mucoidy) in expectorated sputum samples. Under laboratory
conditions, the expression profiles of P. aeruginosa strains differed
in ways that corresponded to phenotypic characteristics such as
mucoidy. By analyzing sputum samples compared to P. aerugi-
nosa strains grown in vitro, we found significant differences, in-
cluding an altered transcript profile associated with alginate pro-
duction, elevated levels of biofilm-associated transcripts and
specific iron acquisition pathways, lower levels of quorum-sens-
ing pathways, and increased expression of certain virulence-asso-
ciated transcripts. Consistent with each subject being culture pos-
itive for mucoid P. aeruginosa, the in vivo profiles were more
similar to mucoid P. aeruginosa than to P. aeruginosa strains with
LasR or classical phenotypes. There were no specific transcrip-
tional changes associated with the inhaled antibiotic regimen used
in the preceding month or in association with clinically meaning-
ful changes in respiratory symptoms (24). The expression patterns
in the sputum samples most closely clustered with each other,
even across subjects with infections by different P. aeruginosa
strains, leading us to propose the hypothesis that there is a com-
mon in vivo profile for the transcripts measured that transcends
strain differences in this cohort (i.e., adults with CF who regularly
expectorate sputum). This paper also includes several validation
assays, including those that demonstrate reproducibility and con-
cordance with data obtained by transcriptome sequencing (RNA-
Seq) that may serve as a framework for future applications of this
technology. Furthermore, we highlight the need for consideration
of strain-to-strain variation and present an analysis of different
methods used for normalization among samples, which is a par-
ticular consideration in the analysis of clinical samples where the
amounts of pathogen RNA are not known.
MATERIALS AND METHODS
Patient recruitment and collection of sputum samples. For the collec-
tion of serial sputum samples, four adult subjects from the New Hamp-
shire CF Center with a history of at least one sputum culture positive for P.
aeruginosa consented to participate in a protocol that was approved by the
CPHS at Dartmouth College (CPHS 23645). All subjects provided a spon-
taneously expectorated sputum sample at each of six monthly outpatient
visits. We also asked subjects to complete the teen/adult version of the CF
Questionnaire-Revised (CFQ-R) at each monthly visit. The CFQ-R has
been validated in the CF population as a way of assessing health-related
quality of life (HRQOL) in 12 domains (physical, vitality, emotion, eating,
treatment burden, health perspectives, social, body image, role, weight,
respiratory, and digestive) (24). Scores in each domain range from 0 to
100, and higher scores signify better health. Each of the four subjects had
P. aeruginosa-positive cultures throughout the 6-month study period. Iso-
lates of P. aeruginosa were collected under protocol 20786.
Strains and growth conditions. Detailed information on strains used
in this study can be found in Table S1 in the supplemental material. P.
aeruginosa strains were grown either in liquid LB-Lennox for 8 h at 37°C
(FRD1, FRD1algU, CI224_M, CI224_nm, CI227, and CI228 strains) or
as colony biofilms on tryptone agar for 24 h at 37°C (PAO1, PA14,
DH1133, DH2415, PAO1lasR, PA14lasR, DH1132, DH2417, CFRL8,
and CFRL11 strains). Data for the wild-type and lasR strain pairs were
also used in analyses published previously (25). Colony biofilms were
inoculated from overnight cultures grown in LB medium at 37°C, and
colonies were inoculated as 5-l spots. Planktonic cultures were inocu-
lated from overnight cultures grown on LB agar plates into 5 ml of LB
medium for 10 h at 37°C. Cultures were then diluted 100 into 10 ml of
prewarmed LB medium and incubated for 2.5 h at 37°C. The optical
density at 600 nm (OD600) was measured, and cultures were adjusted to an
initial OD600 of 0.001, grown in 25 ml of prewarmed LB at 37°C, and
harvested for RNA isolation when they reached an OD600 of 1 (8 to 11 h,
depending on the strain).
Isolation of total RNA. Sputum samples were frozen and stored
at 80°C until the time of RNA isolation. Samples were lyophilized in
original specimen cups and lysed (5 times for 1 min each with 2 min on ice
between rounds) using a mixture of 0.1-mm, 0.5-mm, and 1-mm beads in
a Biospec mini-beadbeater 16 (Biospec Products, Bartlesville, OK). Sam-
ples were then resuspended in TRI Reagent (Zymo Research Corporation,
Irvine, CA). RNA was extracted using Direct-zol RNA MiniPrep kits
(Zymo Research Corporation, Irvine, CA) according to the manufactur-
er’s instructions. The RNA from laboratory cultures was isolated as de-
scribed above without the prior lyophilization step.
Nanostring analysis of P. aeruginosa transcripts. We analyzed RNA
using the Nanostring nCounter system (Nanostring Technologies, Seat-
tle, WA) and methods described by Geiss et al. (26). We employed a
custom-designed codeset containing 75 P. aeruginosa genes (see Table S2
in the supplemental material). The nucleotide sequences were provided to
Nanostring Technologies, Inc., for codeset design and construction. Each
reaction mixture contained 70 ng of RNA for P. aeruginosa from in vitro-
grown cultures and 180 ng of RNA extracted from sputum in 5 l, hy-
bridization buffer, reporter probes, capture probes, as well as six positive
and eight negative controls. RNA was hybridized with reporter and cap-
ture probes overnight at 65°C, and sample preparation ensued at the
Nanostring preparation station. Finally, targets were counted on the
nCounter using 255 fields of view per sample. Data were analyzed using
nSolver Analysis Software, version 1.1 (Nanostring Technologies, Seattle,
WA). Raw counts were normalized to the arithmetic mean of six spiked
positive-control transcripts, and count values greater than two standard
deviations above the average of the eight negative-control probes were
considered above background.
RNA sequencing analysis. RNA quality and quantity were assessed by
a Fragment Analyzer (Advanced Analytical, Ankeny, IA) and Qubit (In-
vitrogen, Carlsbad, CA), respectively. Prior to library preparation, rRNA
was removed using the Ribo-Zero rRNA removal kit for bacteria (Epicen-
tre, Madison, WI). Directional RNA-seq libraries were prepared with the
TruSeq stranded mRNA library preparation kit with unique TruSeq in-
dexes. Samples were pooled and sequenced on an Illumina NextSeq500
instrument with the 2X75bp PE sequencing setting (mid-output flow
cell). Raw reads were processed and normalized using the CLC Genomics
Workbench platform (v8.5.1) using the default parameter setting installed
by the manufacturer. All sequences were trimmed and mapped to the
PAO1 (GenBank accession number NC_002516) reference genome from
NCBI using the RNA-Seq analysis tool, and mapped reads were quantile
normalized to control for any differences in library size.
Statistical analyses. One method for the analysis of mRNA levels in
total RNA isolated from either sputum or in vitro-grown P. aeruginosa
cultures was via the normalization of transcript levels to the mean for
rpoD, ppiD, and fbp (Fig. 1, left branch). For these analyses, the Mann-
Whitney-Wilcoxon test was used to compare the transcripts in mucoid
strains to those in nonmucoid strains. In addition, samples were com-
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pared using rank abundance values from 1 to 75 (there were 75 transcripts
in the codeset), with 75 being the most abundant transcript in that sample.
A Kruskal-Wallis test was used to determine differences between mucoid
and nonmucoid strains or LasR-defective and LasR-intact strains. Heat
map analysis was performed using the heatmap.2 function in the gplots
package (v2.14.2) (27). We used the method of Bland and Altman (28) to
examine the variability of differences in transcript rank abundance gen-
erated by RNA-Seq and Nanostring. The principal coordinate analysis
(PCoA) was performed using the pco function with default Euclidean
distance setting in the ecodist package (v 1.2.9) (29) in RStudio
(v 0.98.994) running with R (v 3.1.1). For the analysis of different fliC type
A and type B transcripts, the log2-transformed normalized reads were
compared. To identify transcripts that differed between P. aeruginosa in
sputum and mucoid P. aeruginosa strains grown in vitro, mixed-effect
linear models of rank differences between in vitro-grown mucoid strains
and repeated measures of sputum samples from the four samples were
performed using a mixed-effect linear model (R package nlme, v 3.1.-128
[https://cran.r-project.org/web/packages/nlme/nlme.pdf]) in which pa-
tient was a random factor and mucoidy was modeled as a main effect.
Nucleotide sequence accession number. The raw and processed
RNA-Seq data have been deposited in the NCBI Gene Expression Omni-
bus under accession number GSE83773.
RESULTS
Identification of phenotypic differences among clinical P.
aeruginosa strains by Nanostring RNA analysis. We determined
how P. aeruginosa gene expression profiles compared to strain
colony phenotypes for clinical isolates grown in vitro and analyzed
P. aeruginosa gene expression in sputum from individuals with
CF. Thus, we developed a Nanostring codeset that monitors the
expression of 75 transcripts associated with P. aeruginosa pro-
cesses occurring in CF airway infections, including biofilm forma-
tion, alginate production, iron acquisition, quorum sensing, and
virulence. Levels of each transcript were monitored using a set of
two hybridizing probes complementary to each transcript of in-
terest, with one probe enabling the capture of a transcript and the
other containing a unique fluorescent bar code for transcript enu-
meration. The collection of probes used in this study is referred to
as the PAV2 codeset.
To determine if data obtained using the PAV2 codeset could
identify transcript level differences that correlate with different
strain phenotypes, we analyzed RNA from 15 clinical isolates and
two laboratory strains. These strains included seven strains with
the classical P. aeruginosa colony phenotype (laboratory strains
PAO1 and PA14 and five clinical isolates), four clinical isolates
with the mucoid phenotype associated with alginate overproduc-
tion, and six strains with a LasR loss-of-function phenotype (in-
cluding PA14lasR and PAO1lasR strains and four clinical iso-
lates; see Table S1 in the supplemental material for strain sources).
One strain (CI224_M) was included in both the mucoid and LasR
loss-of-function categories, since it exhibited both phenotypic at-
tributes. Cultures of each strain were grown as described in Ma-
terials and Methods and total RNA was extracted. Seventy nano-
grams of RNA was analyzed using the Nanostring technology, and
the relative levels of each transcript were determined using the
PAV2 codeset. We performed technical replicates for each of three
FIG 1 Analysis of transcript differences between mucoid and nonmucoid strains using the PAV2 Nanostring codeset. The scheme demonstrates the comparison
of results obtained using two different normalization methods. (Left) In one analysis, raw counts were normalized to the mean levels of three housekeeping (HK)
genes (ppiD, fbp, and rpoD). Statistical analyses of transcripts that differed between the mucoid and nonmucoid strains were performed on relative expression
differences (P  0.05 by Mann Whitney Wilcoxon test). The mean normalized counts for each transcript in each group, the fold difference between the means
for the two groups, and the P value for the difference is shown. (Right) Raw counts were ranked in order of abundance from 1 (least abundant) to 75 (most
abundant), and a Kruskal-Wallis test was used to determine which transcripts were significantly different between the mucoid and nonmucoid groups (P  0.05).
The difference in mean rank between the two groups is shown ( Rank). The housekeeping genes that were significantly different between the two groups are
denoted by the superscript “a.”
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P. aeruginosa strains: one with the classical phenotype (CI224_nm
[DH2243]), one mucoid strain (CFRL8 [DH2529]), and one with
the LasR-defective phenotype (CFRL11 [DH2531]). Pairwise
analysis of technical replicates found very high concordance for
transcripts in each strain (see Fig. S1A), and the transcript profiles
were different between strains, as shown in a rank abundance heat
map analysis of counts per transcript (see Fig. S1B), demonstrat-
ing high technical reproducibility.
To assess differences in transcript profiles between strains with
classical, LasR-defective, and mucoid phenotypes, we used a
Mann-Whitney-Wilcoxon test to identify transcripts that were
significantly different (P  0.05) between mucoid and nonmu-
coid groups. Specifically, we compared profiles for strains with
mucoid phenotypes (FRD1, CI228, CI224_M, and CFRL8) to
those for all of the nonmucoid strains (including those with the
classical and LasR-defective strain phenotypes described above)
using count values normalized to the average transcript counts of
three housekeeping genes, fbp, rpoD, and ppiD. Consistent with
the increased production of alginate in the mucoid strains, we
found that levels of transcripts associated with alginate produc-
tion, algD, algI, and algU, were higher in mucoid strains; algD and
algI had the largest fold differences (P  0.05 by Mann-Whitney-
Wilcoxon Test) (Fig. 1, left arm). Levels of three transcripts, ivy
(inhibitor of vertebrate lysozyme), plcR (cotranscribed with plcH,
which encodes a phospholipase C), and fbp (fructose-1,6-bispho-
sphatase), were also significantly higher in the mucoid strains than
the nonmucoid strains. Levels of three transcripts, norC (nitric-
oxide reductase subunit C), flgD (flagellar basal-body rod modi-
fication protein), and rpoD (sigma factor), were significantly
lower in the mucoid strains than nonmucoid strains. Because two
of the nine genes that varied significantly between the mucoid and
nonmucoid groups were the housekeeping transcripts used for
normalization, we concluded that the transcripts we selected for
normalization varied across samples, and we sought another
method for transcript normalization. As an alternative approach
to compare transcript levels between mucoid and nonmucoid
strains, we employed a rank-abundance method that we applied
without normalization to specific transcripts or to total signal. In
the rank abundance analysis, the 75 transcripts were ranked in
terms of their abundance, with rank 1 being the transcript with the
lowest number of raw counts. The Kruskal-Wallis test was then
used to determine which transcripts changed significantly across
samples (P  0.05). Again, transcripts associated with alginate
production (algD, algI, and algU) were the most significantly dif-
ferent (Fig. 1, right arm, and 2A), confirming that rank abundance
analysis detects transcript differences that correlate with strain
phenotype. Analysis based on normalization to housekeeping
genes also found ivy, norC, and flgG to be differentially expressed
(Fig. 1, left arm), as was the case for genes associated with motility
(flgD and flgK) and denitrification (nirS), consistent with the ex-
pectation of reduced flagellar motility and denitrification in mu-
coid strains based on prior publications (30, 31).
Quorum sensing is a regulatory system in which the accumu-
lation of extracellular signaling molecules positively regulates the
expression of many virulence-regulated transcripts in P. aerugi-
nosa. Smith et al. (18) reported that loss-of-function mutations
develop in quorum-sensing and other virulence genes as P. aerugi-
nosa lung infection evolves in CF patients. As we did in the analysis
of the mucoid strains described above, we compared strains with a
LasR loss of function to strains with intact LasR signaling. Predict-
ably, the LasR clinical isolates had significantly lower levels of
LasR-regulated targets (P  0.05 by Kruskal-Wallis Test; see Table
S3 in the supplemental material for data), including those in-
volved in acyl-homoserine lactone production (lasI and rhlI), the
quinolone signaling pathway (pqsA, pqsH, and pqsE), and the
LasR-regulated elastase (lasB). The abundance of transcripts asso-
ciated with production of quorum-sensing-regulated phenazines
(phzA2, phzC, phzH, and phzM) and rhamnolipid (rhlA) was
lower in LasR clinical isolates (Fig. 2B). A number of transcripts
were significantly higher in the LasR strains in this in vitro anal-
ysis, and most of these transcripts are Anr regulated (see Table S3,
sheets 1 and 2) (32). Increased levels of Anr-regulated transcripts
in LasR strains is consistent with the finding that the level of Anr
regulon is higher in strains with QS deficiencies (25).
Comparison of transcript profiles determined by Nanostring
and RNA-Seq. To assess the ability of the PAV2 codeset to identify
differences in relative transcript levels, we performed RNA-Seq on
RNA isolated from two mucoid P. aeruginosa strains, FRD1 and
CI224_M. We then created a subset of the RNA-Seq data set that
included only the transcripts that were also present in the Nano-
FIG 2 Comparison of selected transcripts that differed between P. aeruginosa
strains with different phenotypes. Rank abundance analyses show the most
highly expressed genes in yellow and the least highly expressed genes in red, as
shown in the legend. (A) Subset of genes involved in extracellular carbohydrate
production that differed between mucoid and nonmucoid strains. (B) Subset
of genes associated with quorum sensing in LasR-competent and LasR-defi-
cient strains.
Gifford et al.
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string PAV2 codeset (see Table S4 in the supplemental material) in
order to compare the two data sets. We excluded exoU transcripts,
which appeared to be absent from both strains (FRD1 and
CI224_M), and fliC alleles because of their variation between the
strains (discussed further in the next section). Because Nanostring
probes were not designed to distinguish between two sets of highly
similar paralogs (PA4210 [phzA1] and PA1899 [phzA2], with 98%
identity over 87% of the length of the gene, and PA4212 [phzC1]
and PA1901 [phzC2], with 99% identity over the length of the
gene [see Table S2]), we summed the reads for phzA1 and phzA2
(reported as phzA) and phzC1 and phzC2 (reported as phzC) for
the rank abundance analysis.
To visualize the similarity between RNA-Seq and the Nanos-
tring analyses, we performed a rank abundance heat map analysis
of counts per transcript (see Fig. S2A in the supplemental mate-
rial). We first performed linear regression, which yielded coeffi-
cients of determination (R2) for correlations between RNA-Seq
and Nanostring (see Fig. S2B). For FRD1 and CI224_M, R2 values
were 0.83 and 0.77, respectively, which indicates a very good cor-
relation between the results of the two methods. As pointed out by
Zaki et al. (33), however, this approach may not be sufficient to
assess agreement between two methods. Therefore, we also con-
ducted Bland-Altman analyses to determine bias and agreement
(see Fig. S2C). There was excellent concordance between the mo-
dalities, with only a few transcripts for each strain falling outside
the 95% confidence interval for agreement and only one transcript
(PA3327) was showing a consistent lack of concordance in both
samples. This PA3327 Nanostring probe seems to be strongly un-
derestimating the number of transcripts present in samples.
Nanostring analyses of clinical isolates must consider ge-
nome sequence variation. Because the Nanostring transcript
quantification method is predicated on hybridization, it is impor-
tant to consider variation among target sequences when analyzing
clinical isolates. One set of genes known to vary by sequence type
includes those associated with flagellum biosynthesis. P. aerugi-
nosa strains have one of two sets of flagellar alleles (type A and type
B), and we included probes that would specifically recognize each
type (fliC type A and type B). The probe that recognizes fliC type B
hybridizes to fliC alleles in strains PAO1 and PA14 and had 100%
identity to the fliC allele in 5 of the 12 P. aeruginosa genomes
analyzed (PAO1, PA14, LESB58, DK2, and C3719) (Fig. 3A). The
fliC type A probe corresponded to sequences that were 99 to 100%
identical in the remaining seven P. aeruginosa genomes (PASC2,
RP72, NCGM2.S1, M18, 39016, 2192, and PA7) (Fig. 3A). Previ-
ous studies had shown similar distributions of fliC alleles in clin-
ical isolates (34, 35). As expected based on the sequence identity
between the different fliC alleles and the allele-specific probes,
only fliC type B transcripts were present above the background in
PAO1, PA14, 2415, DH2417, CI227, CI228, FRD1, FRD1algU,
and CFRL8 strains and only fliC type A transcripts were above
background in CFRL8, CI224_M, CI224_nm, DH1133, DH1132,
and CFRL11 strains (Fig. 3B). We showed that mucoidy was
correlated with lower levels of flagellar gene expression (Fig. 1),
and only the present or high-abundance fliC transcript showed
decreased expression in mucoid strains relative to their non-
mucoid comparator (FRD1 versus FRD1algU strain, CI228
versus CI227, and CI224_M versus CI224_nm). While the fliC
transcripts provide an indication of strain type and can reflect
transcriptional status of the flagellar operon, the other flagellar
genes, flgD, flgG, and flgK, do not vary in sequence across strains
(Fig. 3A) and thus provided a strain-independent measure of fla-
gellar gene expression (Fig. 3B).
Other genes within the P. aeruginosa genome show sequence
variation among strains, but the pattern is less binary than that for
fliC. Because the Nanostring method detects transcripts using
probes that hybridize to 80- to 100-bp-long stretches, sequences
with greater than 90% identity across the length of the probe
should be detected when the analysis is performed according to
the manufacturer’s instructions. For 67 of the 75 probe sets in-
cluded in the PAV2 codeset, there was 98% 	 1.5% sequence
identity between the Nanostring probe and the corresponding ge-
nome sequence in 11 P. aeruginosa genomes. PA7 consistently
showed less homology to probe sequences than the other P.
aeruginosa genomes, although it had greater than 90% identity for
all probes except for the phzM probe, which had only 87% identity
over the length of the probe (36). For mucoidy and quorum-
sensing-related transcripts shown in Fig. 2, the sequences corre-
sponding to the probes were 95% identical across all sequenced
P. aeruginosa genomes.
For the remaining eight transcript-specific probe sets in PAV2,
FIG 3 Variation in genomic sequence and expression levels for motility-associated genes. (A) Across 12 P. aeruginosa strains, the fliC gene exists in 2 variants
(type A and type B) that require separate Nanostring probes for detection due to the low sequence identity. Other flagellar genes, flgD, flgG, and flgK, are highly
similar across different P. aeruginosa strains. (B) Rank abundance analyses of P. aeruginosa flagellar genes in clinical isolates and laboratory strains grown in vitro.
The legend indicates the rank abundance of transcript, with 75 indicating the most abundant transcript.
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there was either variability in the presence of the target gene
among P. aeruginosa strains (e.g., exoU, a type III secreted effector
present only in some P. aeruginosa strains) or there was significant
sequence heterogeneity, with some sequences being less than 90%
identical between strains in a Clustal Omega analysis (see Fig. S3 in
the supplemental material). The variable loci were associated with
type III secretion systems and effectors, type VI secretion systems
and effectors, and pyoverdine siderophore biosynthesis. These
structures vary among strains (37–40). This finding suggests that
Nanostring analysis of some transcripts across different genotypes
requires the inclusion of probes that target multiple alleles, as
demonstrated here for fliC, and/or DNA sequence analysis to con-
firm the target sequence will hybridize to the probe.
Acquisition of P. aeruginosa from serial CF sputum samples
and associated data on sputum microbiology and patient status.
We determined if there was variation in P. aeruginosa transcrip-
tional profiles in P. aeruginosa RNA extracted directly from spu-
tum and if there were correlations between transcript profiles and
either health status or specific antibiotic therapies. Serial sputum
samples and health-related quality-of-life data were collected
from four P. aeruginosa-infected subjects at monthly intervals
over the course of 6 months. The subjects included one male and
three females with severe to moderate lung function impairment
(Table 1). All of the sputum cultures detected P. aeruginosa, with
some or all of the colonies from the sample having a mucoid
phenotype. One of the subjects also cultured positive for methi-
cillin-resistant Staphylococcus aureus (MRSA) and the other three
had at least one sputum sample positive for Aspergillus fumigatus
(Table 1). Total RNA was isolated from serial sputum samples
collected monthly from each of four subjects over 6 months. Our
final analysis included four to seven samples in each series. Miss-
ing samples within the series from subjects 10 and 13 were due
either to the subject’s inability to produce a sputum sample at that
office visit or because only small quantities of poor-quality RNA
were recovered from the sample.
Comparison of sputum-derived RNA and RNA from P.
aeruginosa grown in vitro. Studies published by us (21, 41, 42)
and others (19, 43) have demonstrated the ability to measure mi-
crobial mRNAs in total RNA extracted directly from sputum. To
better characterize the quality and amount of the P. aeruginosa
RNA in total RNA from sputum, we compared the total counts for
all 75 transcripts, mean number of counts per transcript, and the
median counts per transcript for the 23 sputum-extracted RNAs
and for the RNA extracted from the 17 in vitro-grown samples.
First, we compared the total counts (the sum of counts for all 75
transcripts). For in vitro-grown P. aeruginosa samples, 70 ng of
total RNA was analyzed by PAV2; for the analysis of total RNA
from sputum, 180 ng of total RNA, which contained RNA from
multiple sources, including the human host, was analyzed (see
Table S5 in the supplemental material). We found that there was
an average of 117,684 total counts per sample for the in vitro-
grown P. aeruginosa samples and an average of 98,010 total counts
per sample in the sputum samples. Based on the comparable levels
of total PAV2 counts and the fact that approximately 2.5-fold
more RNA was analyzed for the sputum samples, we concluded
that P. aeruginosa RNA likely comprised approximately one-
fourth to one-half of the total RNA from sputum. A similar rela-
tionship between the sputum and in vitro sample groups was also
observed when we compared the averages of the mean counts per
transcript per sample. PAV2 analysis of sputum RNAs found, on
average, a mean of 1,569 counts per transcript (with 394 and 4,231
as the minimum and maximum mean counts per transcript, re-
spectively); in vitro-grown samples had an average value of 1,348
mean counts per transcript, with a range between 463 and 2,907
mean counts per transcript for samples in this group (see Table S5
for mean and median count values for each sample).
Our data also indicated that both the in vitro and sputum RNAs
contained transcripts detected at a range of levels. In PAV2 ana-
lysis of both in vitro and sputum RNAs, we found that the average
of the median counts per transcript was 10-fold lower than the
average maximum number of counts for a single transcript within
that group. These large ranges of transcript counts within samples
strongly supports the notion that RNA, rather than DNA, was
being measured. (In DNA, all loci are present in single copy.) In
general, the range of transcript abundances within the in vitro
samples was greater than that in the sputum RNA samples.
Evidence for a common P. aeruginosa sputum profile inde-
pendent of time and strain. A heat map analysis of all 75 tran-
scripts versus a collection of laboratory strains and clinical isolates
revealed a striking similarity observed across sputum samples
from the same subject and from sputum samples from across sub-
jects (Fig. 4A; see also Fig. S5 in the supplemental material for
transcript and sample labels). The concordance across sputum
samples was particularly striking, especially when transcripts that
likely vary at the DNA sequence level between strains were not
considered (Fig. 4A, arrows). A PCoA of all in vitro and in vivo
samples included in this study further illustrated the close cluster-
ing of sputum samples with each other and their distinct cluster-
ing away from clinical isolates grown in vitro (Fig. 4B). While it is
not surprising that there were transcriptional differences between
cells grown in planktonic LB medium and isolates contained in
sputum, it is striking that sputum harboring different strains
(shown in Fig. 5A as described below) collected at various time
points and under various health contexts, as measured by the
TABLE 1 Subject characteristics and culture resultsa
Identifierb Age (yr) Gender BMI FEV1%
Inhaled antibiotic cycle (by month)
1 2 3 4 5 6
10 32 F 20.3 55 P, mP, A P, mP P, mP
13 27 M 21.0 78 P, mP, A P, A
16 24 F 22.7 66 P, mP, MRSA P, mP, MRSA
17 44 F 23.1 32 P, mP, A P, A
a Abbreviations: F, female; M, male; BMI, body mass index; FEV1%, forced expiratory volume in 1 s, expressed as percent predicted; P, P. aeruginosa; mP, mucoid P. aeruginosa;
MRSA, methicillin-resistant S. aureus; A, Aspergillus fumigatus.
b Subjects 10, 13, and 17 were CFTRF508 heterozygous, and subject 16 was CFTRF508 homozygous.
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CFQ-R respiratory symptom score (RSS) (see Fig. S4 and Table
S6), had largely similar profiles for the 75 transcripts.
Analysis of similarities and difference between sputum-de-
rived and in vitro-grown P. aeruginosa RNA. To compare the P.
aeruginosa PAV2 profiles for mRNA from sputum to the mRNAs
from in vitro-grown P. aeruginosa, we analyzed the data for all
samples by rank abundance and visualized the data as a heat map
(see Fig. S4 in the supplemental material, which used data shown
in Table S5). First, we analyzed the strain-specific fliC transcripts.
Analysis of the relative counts for the fliC type A and type B alleles
showed that three of the individuals were colonized by strains with
fliC type A alleles and one subject was colonized by a strain(s) with
an fliC type B allele. There were no instances of a shift from an fliC
type A and type B population within an individual across the serial
samples from that subject (Fig. 5A).
All subjects had positive clinical sputum cultures for the mu-
coid P. aeruginosa (Table 1). Of the 75 transcripts analyzed, the
algD transcript, which is involved in production of the exopoly-
saccharide alginate, was highly abundant in all of the sputum sam-
ples (Fig. 5B). Transcript levels for algU, which encodes a gene
product that positively regulates both its own transcription and
that of algD, were also uniformly high (44, 45). While algI was also
among the most abundant transcripts in mucoid strains relative to
nonmucoid strains in the in vitro samples, algI was not at high
relative abundance in P. aeruginosa RNA isolated from sputum
across all 23 samples from four independent subjects. AlgI is in-
volved in alginate acetylation and is not required for alginate bio-
synthesis (46), and these data suggest that the transcription or
stability of algI is modulated in the in vitro environment.
In our analysis of mucoid versus nonmucoid strains grown in
vitro, we found a significant negative correlation between alginate-
associated transcript levels and flagellar transcript levels. Interest-
ingly, flgK, flgG, and flgD were at higher rank abundance in the
sputum RNAs than in RNAs from the mucoid strains grown in
vitro in liquid medium, suggesting the presence of subpopulations
within the sputum sample with elevated flagellar expression or
that there is higher flagellar gene expression relative to alginate
gene expression in P. aeruginosa in the lung (47). When the spu-
tum RNAs were compared to the in vitro profiles of the mucoid
strains grown in LB with aeration at 37°C, we found that algI was
significantly different but algD and algU were not (Fig. 5B). ivy, a
transcript found to be significantly more abundant in mucoid
strains than in nonmucoid strains in the in vitro analysis, was at
similar relative abundance in sputum RNAs and in RNA from
mucoid strains grown in vitro.
Analysis of quorum-sensing-associated genes in sputum-de-
rived P. aeruginosa RNA. Variation in the relative levels of quo-
rum-sensing-related genes was observed between subjects. For ex-
ample, in subject 17, we observed lower sputum levels of the
transcripts encoding enzymes involved in the synthesis of key
quorum-sensing signals (lasI, rhlI, and pqsA) than in subjects 10,
13, and 16 (Fig. 5C), suggesting the presence of a QS-defective
FIG 4 Comparisons of transcript profiles across in vivo and in vitro samples obtained using the PAV2 Nanostring codeset. (A) Simplified rank abundance heat
map of all transcripts in all samples analyzed. The detailed heatmap with all sample identifiers and all transcript names is presented in Fig. S3 in the supplemental
material. For the in vitro samples, the strain phenotype (classical, mucoid, or LasR deficient) is shown. For the in vivo samples, the subject number and treatment
code (A, aztreonam; C, colistimethate; T, tobramycin; and N, no treatment) is shown. Transcripts that likely vary at the DNA sequence level between strains are
indicated by arrows: 1, fliC type B and fliC type A, respectively; 2, popB; 3, exoU and pscC (top and bottom); 4, pldA; 5, pvdA; 6, PA4929. (B) Principal-component
analysis of the ranks of all PAV2 transcripts in all in vivo and in vitro samples. All in vivo (black) samples cluster together and are distinct from the in vitro samples.
The in vitro samples can be separated into three clusters: the classical strains, including the laboratory strains PAO1 and PA14 (in green), the mucoid strains (in
red), and the LasR-deficient strains (in blue). CI224_M is both mucoid and LasR deficient and is located between both clusters and labeled in red text surrounded
by a blue line.
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mutant (48, 49) in subject 17. In subject 13, the relative abundance
levels of rhlI, pqsA, and pqsE fluctuated over the serial samples,
while no other transcripts showed a similar pattern, raising the
question of whether population-level changes occur over time. A
comparison of all of the sputum RNA profiles to profiles of mu-
coid strains grown in vitro found a statistically significant trend
with lower levels of quorum-sensing-regulated transcripts in spu-
tum RNA compared to strains grown in vitro (Fig. 5C). While the
levels of some of the quorum-sensing-controlled genes measured
here were lower than levels in mucoid strains grown in vitro, in-
cluding hcnA, involved in cyanide biosynthesis, lasB, which en-
codes an elastase, and rhlA, associated with rhamnolipid biosyn-
thesis (50), the phenazine biosynthetic genes phzA, phzC, phzM,
and phzH were among the most abundant transcripts in all sam-
ples and were not at levels lower than those in in vitro cultures.
(Fig. 5C). The finding that phenazine-associated transcripts were
high is consistent with the detection of high levels of redox-active
small-molecule phenazines in CF sputum (50). The disconnection
between phenazine-related transcript levels and other quorum-
sensing-associated transcripts suggests a mode of regulation that
is not directly correlated with levels of QS. Future studies will
determine if this type of profile is associated with variation in
dominant P. aeruginosa populations or changes in the environ-
ment in the lung (discussed in more detail below).
Biofilm-associated transcripts in sputum-associated RNA.
Transcripts encoding the biofilm matrix carbohydrates Pel and Psl
were at a lower rank abundance than the alg genes (Fig. 5A). pelA
transcripts were present at a significantly higher relative abun-
dance in RNA isolated from sputum than from mucoid strains
grown in culture (Fig. 5D). Transcripts associated with the pro-
duction of CupA fimbriae, a surface appendage also associated
with biofilm formation, were also more highly expressed in spu-
tum than in in vitro cultures (Fig. 5D). Transcription of the
cupA1-5 operon and cgrA-C, which encodes the cupA regulator, is
controlled by Anr, an oxygen-responsive regulator (25, 32, 51).
Virulence-associated transcripts in sputum-associated RNA.
Previous work has shown high expression of genes associated with
production and activity of PlcH, a hemolytic phospholipase C, in
RNAs from CF sputum (52). Consistent with this finding, plcH
and plcR were at higher rank abundance in the sputum RNAs than
the RNAs from in vitro-grown cultures. The transcript encoding
the choline phosphate phosphatase, which acts on choline phos-
phate (the product of PlcH activity), also showed this trend. Sim-
ilarly, levels of transcripts associated with the type III secretion
system (pscC and popB) were significantly higher in the sputum
RNAs than in the mucoid RNAs from strains grown in culture.
The level of transcript encoding the T3SS effector ExoT was not
significantly higher in sputum RNAs than in RNA from mucoid
strains, and none of the samples had detectable levels of exoU, a
potent type III-secreted cytotoxin that is present only in a subset of
P. aeruginosa strains (53). The level of transcript encoding cif was
also significantly higher (P  0.05) in RNA from sputum than
from in vitro-grown cultures (Fig. 5E).
Profiles associated with iron acquisition by P. aeruginosa in
vivo. Because numerous studies have found links between iron
availability and the state of CF lung disease (50, 54–56), we exam-
ined transcripts associated with iron metabolism by analyzing lev-
els of hasR, phuR, pchC, feoB, and pvdA. The levels of transcripts
hasR and phuR were significantly higher (P  0.05) in P. aerugi-
nosa RNA from sputum than in RNA from in vitro-grown mucoid
strains, LasR strains, or classical phenotypes (Fig. 5F) where
pchC (involved in pyochelin biosynthesis) and feoB (involved in
ferrous iron uptake) were not significantly different. Because
pvdA, which encodes L-ornithine N5-oxygenase, involved in py-
FIG 5 P. aeruginosa gene expression in vivo in serial sputum samples from
four CF subjects and in P. aeruginosa strains grown in vitro. (A) Detection of
different fliC gene alleles present among CF subjects. Note that log2-trans-
formed normalized reads were used in the comparison of levels of the fliC type
A and B alleles. The flagellar type remained constant within a subject across the
series. (B to F) Rank abundance analysis indicating levels of transcripts (most
abundant in yellow and least abundant in red). Panels show subsets of genes
involved or coregulated with extracellular carbohydrate production (B), quo-
rum sensing (C), biofilm formation (D), virulence (E), and iron acquisition
(F). The sample and strain names are along the bottom. For the in vivo samples,
the first number indicates the subject (10, 13, 16, and 17), and the number
following the “V” indicates the visit number within the 6-month enrollment
period. Letters above each in vivo sample column denote the type of inhaled
antibiotic used at the time of sample collection (A, aztreonam; C, colistimeth-
ate; T, tobramycin; and N, no treatment). The in vivo samples (RNA extracted
from sputum) and in vitro mucoid strains were compared, and the genes high-
lighted in boldface were statistically differentially ranked following correction
for multiple hypotheses (false discovery rate-corrected P value of 0.05).
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overdine biosynthesis (57), can vary in sequence based on the type
of Pvd cluster present (39) (see Fig. S3 in the supplemental mate-
rial), we speculate that the striking differences in pvdA levels
across subjects also reflect gene sequence differences. The higher
expression of hasR and phuR is consistent with the utilization of
heme as an iron source when P. aeruginosa is in the CF lung (58).
DISCUSSION
This study describes the novel application of multiplexed Nanos-
tring technology to quantify P. aeruginosa mRNA transcripts in
CF sputum samples. We showed that Nanostring analysis could
detect variation in the expression pattern of 75 transcripts in phe-
notypically different P. aeruginosa strains, in samples from differ-
ent subjects, and in samples collected at different time points from
the same subject. Quantifying gene expression by the Nanostring
method is efficient and avoids the potentially confounding effects
of in vitro culture conditions. Analysis of the total counts for the 75
transcripts indicated that P. aeruginosa RNA comprised 25 to 50%
of the RNA in most samples. Our analysis of bulk sputum allows
for the analysis of transcripts that represent multiple key pathways
at the population level in samples from the CF lung, and while we
are only measuring 75 transcripts in this study, the RNA sample
subsequently could be analyzed by other methods, including ad-
ditional Nanostring codesets, quantitative reverse transcription
PCR, or whole-transcriptome profiling methods. The transcrip-
tional signatures that we obtained from the analysis of serial spu-
tum samples from four subjects provided a picture that was con-
sistent with other studies that analyzed P. aeruginosa directly in
sputum. For example, we found evidence for production of alg-
inate and nonalginate exopolysaccharides (59, 60), phospholipase
C (21), phenazines (61), and iron-scavenging compounds (62)
in vivo.
P. aeruginosa isolates from CF patients are heterogeneous. For
example, by analyzing 34 sputum samples collected from a single
CF patient over the span of 1 year, Workentine et al. (63) identi-
fied significant phenotypic variation among P. aeruginosa isolates
with the same colony morphotype (i.e., mucoid or nonmucoid),
even when they came from the same sample. As further evidence
of P. aeruginosa phenotypic variability in CF sputum, colonies of
the same morphotype often have different in vitro antibiotic sus-
ceptibility profiles (9, 64). Thus, accurate characterization of the
phenotype of the P. aeruginosa population in vivo has been elusive.
While these methods do not provide resolution at the level of
single cells or subpopulations with a common genotype, the
largely uniform profiles across serial samples from the same sub-
ject, despite differences in therapy or respiratory health, and even
across subjects, suggests that the lung environment induces a
common response in the majority of cells in CF sputum.
Several lines of evidence suggest that P. aeruginosa exists in a
biofilm-like state in the lung and that in vivo biofilm lifestyle in-
fluences its susceptibility to drugs (65–67). Antibiotics only mod-
estly or transiently alter microbial community structure in the
lungs of CF patients despite improvements in health status (68–
70). These observations led us to question whether the salubrious
effects of antibiotics were associated less with their microbicidal
activity and more with how they affect bacterial phenotypes in the
lung, as evidenced by their gene transcription profiles. To deter-
mine if specific transcripts varied in relation to antibiotic treat-
ment (see Fig. S5 in the supplemental material) over the preceding
month or health status at the time of visit, we analyzed the sputum
transcriptional profiles in relation to these data. A comparison of
samples collected after a common drug regimen (e.g., tobramy-
cin) did not find transcripts that showed significant correlations
with the type of inhaled drug over the preceding month (data not
shown). While we did not see significant differences in profiles
that correlated with use or abstinence from a particular antibiotic,
the samples collected in this study were taken at the end of a
30-day period on the indicated treatment (antibiotic or no inhaled
antibiotic). Future studies will determine if changes in P. aerugi-
nosa profiles are evident earlier after a change in treatment, as it is
possible that cells in chronic infections return to a steady state
after sustained antibiotic exposure.
Much of the literature pertaining to the CF sputum micro-
biome has demonstrated that bacterial richness and abundance
vary modestly despite changes in clinical status and antibiotic
treatment (68, 69, 71). In this study, each subject had at least one
set of sequential samples for which there was a clinically relevant
change in CFQ-R RSS (4 points) (72–78) (see Fig. S4 in the
supplemental material). We employed the CFQ-R because it is a
generally accepted framework for discussing health-related qual-
ity of life for this disease (79–81). Whether the ebb and flow of
respiratory symptoms in CF are associated with changes in micro-
bial gene transcription is not yet known. Here, we did not observe
discrete transcriptional patterns among these 75 transcripts that
correlated with differences in patient respiratory health, but addi-
tional studies are required in order to determine whether P.
aeruginosa gene expression varies between periods of disease sta-
bility or disease exacerbation.
Based on our successful application of the Nanostring plat-
form to the analysis of sputum mRNA transcripts, we propose
that the use of codesets for additional genes reveals differences
in the abundance of specific P. aeruginosa transcripts between
subjects. Use of other codesets indicates the utility of different
treatments or may be able to indicate, at an early time point,
when therapy is working. Similar approaches to personalized
medicine using the Nanostring platform have recently been
advanced for children with septic shock in which glucose up-
take pathways were analyzed (82) and for women with early-
stage breast cancer (83). The ability to ascertain whether a CF
patient harbors P. aeruginosa that is iron starved stands to in-
form the use of inhaled iron chelators. Conversely, the mRNA
signature of a quorum-sensing mutant (Fig. 5C, subject 17)
might predict diminished efficacy of quorum-sensing inhibi-
tors under investigation (84). Clinicians generally select anti-
biotics to treat infections based on the in vitro susceptibility
profiles of bacteria isolated in the laboratory. However, this
paradigm is no more effective than empiricism in those with CF
and P. aeruginosa infection (64, 85, 86), highlighting the need
for novel approaches.
This technology allows for the analysis of numerous transcripts
(dozens to hundreds) in a nonenzymatic analysis that negates the
need to eliminate contaminating DNA from clinical samples.
Thus, this methodology is a very useful complementary approach
to the analysis of transcripts using global profiling methods such
as microarray (43) or RNA-Seq, in that it allows for the rapid and
easy analysis of many clinical samples. Furthermore, rapid sample
preparation makes it possible to analyze small amounts of mate-
rial that would be insufficient for a broader analysis.
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